Takeover Target, page-4

DOJ issues are with most pharma companies. There's more than just Mayne listed in the law suit/s.
Remember, the accusations are for price fixing in the doxycycline generic space. It's not a huge impact, even if MYX lose the law suit to be honest...
In fact, if this causes some manufacturers to pull out of manufacturing a doxy generic, it may boost revenues in the Doryx MPC space.

Customer consolidation can be negated by consolidation on the supply side (manufacturer/distribution) as well. So a takeover supports this theory - although I'm not sure it can be sold to investors (if additional capital is required) in the current deflationary environment.


Forgetting the fact that a buyout for Mayne is extremely unlikely (and a poor reason to make an investment decision), the insider ownership is basically enough to put a stop to it. In any case, it would be a real shame if this was taken over.